A Novel Extraction Procedure Using Micro Elution Plates for the Estimation of Docetaxel Using UPLC and ACQUITY TQD

Significance of the Topic

Docetaxel is a widely prescribed taxane chemotherapy agent for breast, ovarian, and non-small cell lung cancers. Its strong microtubule-binding affinity and high protein binding in plasma make accurate quantification challenging. Reliable bioanalysis of docetaxel at low concentration levels is essential for pharmacokinetic studies, therapeutic drug monitoring, and ensuring patient safety. High-throughput, sensitive, and robust analytical workflows streamline drug development and clinical research.

Objectives and Study Overview

This work aims to develop and validate a rapid, sensitive UPLC–MS/MS method using micro-elution solid phase extraction for docetaxel measurement in human plasma. Key goals include minimizing plasma volume requirements, achieving low limits of quantification (LLOQ), and demonstrating linearity, accuracy, and reproducibility across a wide concentration range (200 pg/mL to 100 ng/mL).

Methodology and Instrumentation

Sample Preparation:

• 300 µL human plasma diluted with water and centrifuged.
• Centrifuged supernatant loaded onto Oasis HLB micro-elution plates.
• Conditioning: organic solvent and water.
• Washing: two aqueous rinses and one organo-aqueous rinse.
• Elution with organic solvent; direct injection into UPLC.
  

Chromatographic Conditions:

• System: ACQUITY UPLC.
• Column: ACQUITY UPLC BEH C8 (1.7 µm, 2.1×100 mm) at 40 °C.
• Mobile phase gradient: 70% aqueous buffer to 90% organic over 4.2 min, then return to initial composition.
• Flow rate: 0.3 mL/min; injection volume: 20 µL.
  

Mass Spectrometry:

• Detector: ACQUITY TQ Detector.
• Ionization: ESI positive mode.
• MRM transitions for docetaxel: m/z 808.7 → 226.3 and 808.7 → 282.3.

Key Results and Discussion

Retention time for docetaxel was 2.67 min with a peak width of 10 s. At the LLOQ (200 pg/mL), the average signal-to-noise ratio across six replicates was ~196, indicating excellent sensitivity. Calibration curves were linear (r²≥0.9994) over four orders of magnitude. Back-calculated concentrations stayed within ±12% of nominal values. Extraction recovery for both docetaxel and internal standard averaged 48% across LLOQ, low (LQC), mid (MQC), and high (HQC) QC levels, with coefficient of variation ≤10%. Inter-batch reproducibility evaluations in three independent runs yielded accuracy >93% at all QC levels and %CVs below 10%.

Advantages and Practical Applications

This micro-elution SPE approach reduces plasma consumption and matrix effects, while maintaining clean extracts and high assay sensitivity. The streamlined protocol suits high-throughput drug monitoring and pharmacokinetic investigations. The combination of Oasis HLB micro-elution plates with ACQUITY UPLC and TQD delivers rapid turnaround, reliable quantitation at sub-ng/mL levels, and robust performance for routine bioanalysis laboratories.

Future Trends and Potential Applications

Emerging trends include miniaturized SPE devices combined with UHPLC–MS for multiplexed drug panels and biomarker profiling. Integration with automated liquid handling platforms will further boost throughput. Advances in high-resolution MS and data-independent acquisition could enhance selectivity for complex matrices. Such innovations will broaden applications in clinical pharmacology, toxicology, and personalized medicine.

Conclusion

A validated UPLC–MS/MS method using micro-elution extraction reliably quantifies docetaxel in human plasma with high sensitivity and throughput. The protocol demonstrates linearity across four orders of magnitude, precise accuracy, and consistent recovery, offering a robust tool for pharmacokinetic studies and therapeutic monitoring.

Instrumentation

• Oasis HLB Micro-elution Plates
• ACQUITY UPLC System
• ACQUITY UPLC BEH C8 Column (1.7 µm, 2.1×100 mm)
• ACQUITY TQ Detector